Disease stratification in idiopathic pulmonary fibrosis: The dawn of a new era?

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1233-1236

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; CYTOKINE; LYSYL OXIDASE LIKE 2 PROTEIN; PROTEIN LYSINE 6 OXIDASE; SIMTUZUMAB; UNCLASSIFIED DRUG; LOXL2 PROTEIN, HUMAN; OXIDOREDUCTASE;

CELL ACTIVATION; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; BLOOD; FEMALE; MALE;

AMINO ACID OXIDOREDUCTASES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE;

EID: 84899809490     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00228513     Document Type: Review

References (23)

1. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013; 22: 148-152.
2. Richeldi L, Collard HR, du Bois RM, et al. Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. Eur Respir J 2013; 42: 230-238.
3. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835-839.
4. Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013; 41: 1207-1218.
5. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269.
6. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
7. Maher TM. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr Opin Pulm Med 2013; 19: 460-465.
8. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013; 93: 252-259.
9. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
10. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
11. Wheelock CE, Goss VM, Balgoma D, et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. Eur Respir J 2013; 42: 802-825.
12. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832.
13. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012; 40: 101-109.
14. du Bois RM, Albera C, Bradford WZ, et al. 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421-1429.
15. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
16. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 717-723.
17. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11: 164-168.
18. Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69-83.
19. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43: 1430-1438.
20. Yamauchi M, Shiiba M. Lysine hydroxylation and cross-linking of collagen. Methods Mol Biol 2008; 446: 95-108.
21. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nature Med 2010; 16: 1009-1017.
22. Makawita S, Dimitromanolakis A, Soosaipillai A, et al. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer 2013; 13: 404.
23. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158: 641-649.